Thiol Disulfide Balance and Oxidative Stress Change in Endometrial Polyp Patients

Changes in Thiol Disulfide Balance and Oxidative Stress Mechanisms in Patients with Endometrial Polyps

Study Overview

• Status: Completed
• Conditions: Oxidative Stress; Endometrial Polyp

• Study Type: Observational
• Enrollment (Actual): 54

Contacts and Locations

Study Locations

• Turkey
  • Antalya, Turkey
    • Alanya Training and Research Hospital Gynecology and Obstetrics Department

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

A total of fifty-four participants, aged 20 to 48, took part in the study, including twenty-four women diagnosed with endometrial polyps and thirty women as the control group.

Description

Inclusion Criteria:

For participants in the control group:

• To be without endometrial polyp

For the polyp group, they were as follows:

• Individuals experiencing menometrorrhagia
• A body mass index (BMI) of 25 or more
• Hypertension
• Endometrial polyps detected via saline infusion ultrasonography

Exclusion Criteria:

• Pregnancy
• Diabetes mellitus
• Pelvic mass
• Malignancy
• The use of Tamoxifen, hormonal contraceptives, or hormone replacement therapy.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
endometrial polyps; Women with endometrial polyp
control group; Participants in the control group were confirmed to be free of endometrial polyps via TVUSG and saline infusion ultrasonography

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Oxidative stress markers	Total antioxidant status (μmol Trolox equivalent/ L)	From January 2021 to January 2022
Oxidative stress markers	Total oxidant status (μmol H2O2 equivalent/L)	From January 2021 to January 2022
Oxidative stress markers	Oxidative stress index (arbitrary unit)	From January 2021 to January 2022
Oxidative stress markers	Paraoxonase (U/L)	From January 2021 to January 2022
Oxidative stress markers	Arylesterase (Ku/l)	From January 2021 to January 2022
Oxidative stress markers	Total thiol (µmol / L)	From January 2021 to January 2022
Oxidative stress markers	Native thiol (µmol / L) / alb (g / l)	From January 2021 to January 2022
Oxidative stress markers	Disulfide (-S-S-) (µmol / L) / alb (g/l)	From January 2021 to January 2022
Oxidative stress markers	Ischemia-modified albumin (u/L)	From January 2021 to January 2022

Collaborators and Investigators

• Sponsor: Mardin Artuklu University

Study record dates

Study Major Dates

• Study Start (Actual): January 2, 2021
• Primary Completion (Actual): January 3, 2022
• Study Completion (Actual): January 5, 2022

Study Registration Dates

• First Submitted: February 7, 2025
• First Submitted That Met QC Criteria: February 12, 2025
• First Posted (Actual): March 25, 2025

Study Record Updates

• Last Update Posted (Actual): March 25, 2025
• Last Update Submitted That Met QC Criteria: February 12, 2025
• Last Verified: February 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Pathological Conditions, Anatomical; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Uterine Diseases; Genital Diseases, Female; Genital Neoplasms, Female; Uterine Neoplasms; Polyps
• Other Study ID Numbers: 10354421-2020/23-8

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No